Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
MNOV's Cash-to-Debt is ranked higher than
85% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: 49.39 vs. MNOV: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MNOV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.67  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
MNOV's Interest Coverage is ranked higher than
87% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MNOV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MNOV' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 12.11
Beneish M-Score: -3.76
WACC vs ROIC
2.01%
-100.45%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -30.26
MNOV's ROE % is ranked lower than
54% of the 544 Companies
in the Global Biotechnology industry.

( Industry Median: -24.74 vs. MNOV: -30.26 )
Ranked among companies with meaningful ROE % only.
MNOV' s ROE % Range Over the Past 10 Years
Min: -73.58  Med: -42.52 Max: -19.99
Current: -30.26
-73.58
-19.99
ROA % -26.54
MNOV's ROA % is ranked lower than
53% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: -21.99 vs. MNOV: -26.54 )
Ranked among companies with meaningful ROA % only.
MNOV' s ROA % Range Over the Past 10 Years
Min: -52.77  Med: -30.28 Max: -16.41
Current: -26.54
-52.77
-16.41
ROC (Joel Greenblatt) % -18601.03
MNOV's ROC (Joel Greenblatt) % is ranked lower than
92% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: -218.94 vs. MNOV: -18601.03 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNOV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27190.77  Med: -5635.72 Max: -109.01
Current: -18601.03
-27190.77
-109.01
3-Year Revenue Growth Rate -100.00
MNOV's 3-Year Revenue Growth Rate is ranked lower than
96% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. MNOV: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MNOV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -100
Current: -100
3-Year EBITDA Growth Rate 20.10
MNOV's 3-Year EBITDA Growth Rate is ranked higher than
71% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. MNOV: 20.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNOV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -83.3  Med: -26.3 Max: 188.9
Current: 20.1
-83.3
188.9
3-Year EPS without NRI Growth Rate 20.20
MNOV's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. MNOV: 20.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MNOV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -86.2  Med: -26.8 Max: 254
Current: 20.2
-86.2
254
GuruFocus has detected 2 Warning Signs with MediciNova Inc $MNOV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNOV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MNOV Guru Trades in Q4 2015

Jim Simons 98,200 sh (-4.75%)
» More
Q1 2016

MNOV Guru Trades in Q1 2016

Jim Simons 100,100 sh (+1.93%)
» More
Q2 2016

MNOV Guru Trades in Q2 2016

Jim Simons 34,500 sh (-65.53%)
» More
Q3 2016

MNOV Guru Trades in Q3 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MNOV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:ABEO, NAS:CYAD, OTCPK:SPHRY, OTCPK:SPRWF, NAS:CGEN, OTCPK:VNLPY, OTCPK:OXBDF, OTCPK:THERF, NAS:NVLN, NAS:AUPH, NAS:AVXL, NAS:IMGN, NAS:MDGL, OTCPK:BNRPF, OTCPK:ELVAF, OTCPK:SIGA, NAS:MNKD, NAS:VBIV, NAS:IDRA, NAS:GNMX » details
Traded in other countries:RMN.Germany, 4875.Japan,
MediciNova Inc is a biopharmaceutical company. It is engaged in acquiring and developing small molecule therapeutics for the treatment of serious diseases with unmet medical needs.

MediciNova Inc was incorporated in the State of Delaware in September 2000.It is a biopharmaceutical company focused on developing novel, small molecule therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the U.S. market. The Company operates in a single operating segment - the acquisition and development of small molecule therapeutics for the treatment of serious diseases with unmet medical needs. The Company currently focuses its development activities on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and substance dependence (e.g.,methamphetamine dependence, opioid dependence, and alcohol dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). Its pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

Ratios

vs
industry
vs
history
PB Ratio 6.44
MNOV's PB Ratio is ranked lower than
69% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. MNOV: 6.44 )
Ranked among companies with meaningful PB Ratio only.
MNOV' s PB Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.33 Max: 9.45
Current: 6.44
0.18
9.45
Current Ratio 15.16
MNOV's Current Ratio is ranked higher than
91% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. MNOV: 15.16 )
Ranked among companies with meaningful Current Ratio only.
MNOV' s Current Ratio Range Over the Past 10 Years
Min: 1.59  Med: 9.71 Max: 31.27
Current: 15.16
1.59
31.27
Quick Ratio 15.16
MNOV's Quick Ratio is ranked higher than
91% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. MNOV: 15.16 )
Ranked among companies with meaningful Quick Ratio only.
MNOV' s Quick Ratio Range Over the Past 10 Years
Min: 1.59  Med: 9.71 Max: 31.27
Current: 15.16
1.59
31.27

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -15.30
MNOV's 3-Year Average Share Buyback Ratio is ranked lower than
63% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. MNOV: -15.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNOV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -520.6  Med: -15 Max: 0
Current: -15.3
-520.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 11.71
MNOV's Price-to-Net-Cash is ranked lower than
60% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 7.38 vs. MNOV: 11.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MNOV' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.87  Med: 4.94 Max: 19.45
Current: 11.71
0.87
19.45
Price-to-Net-Current-Asset-Value 11.50
MNOV's Price-to-Net-Current-Asset-Value is ranked lower than
66% of the 387 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. MNOV: 11.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MNOV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.83  Med: 4.65 Max: 11.63
Current: 11.5
0.83
11.63
Price-to-Tangible-Book 11.10
MNOV's Price-to-Tangible-Book is ranked lower than
77% of the 494 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. MNOV: 11.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MNOV' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.4  Med: 4.37 Max: 60.74
Current: 11.1
0.4
60.74
Earnings Yield (Greenblatt) % -5.45
MNOV's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. MNOV: -5.45 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNOV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -5.8  Med: 98.1 Max: 8448.3
Current: -5.45
-5.8
8448.3

More Statistics

EPS (TTM) $ -0.33
Beta-0.05
Short Percentage of Float8.82%
52-Week Range $4.55 - 10.16
Shares Outstanding (Mil)34.53
» More Articles for MNOV

Headlines

Articles On GuruFocus.com

More From Other Websites
6:02 pm MediciNova and the JASDAQ Market announced 'positive results' from in vitro study that... Feb 27 2017
MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th... Feb 27 2017
MNOV: MN-166 Making Progress in Numerous Indications… Feb 27 2017
MEDICINOVA INC Financials Feb 18 2017
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure Feb 15 2017
MEDICINOVA INC Files SEC form 10-K, Annual Report Feb 14 2017
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the American... Feb 07 2017
MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine... Feb 06 2017
MediciNova to Attend Mizuho Healthcare Conference in New York Feb 01 2017
MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence Jan 23 2017
MNOV: Phase 2b Trial of MN-166 in Progressive MS Will Continue to Conclusion Dec 22 2016
MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166... Dec 20 2016
MediciNova Announces European Commission Grants Orphan Medicinal Product Designation for MN-166... Dec 20 2016
MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned... Dec 19 2016
MediciNova Announces Phase 2b Trial of MN-166 (ibudilast) in Progressive MS will Continue as Planned... Dec 19 2016
MediciNova, Inc. :MNOV-US: Earnings Analysis: Q3, 2016 By the Numbers : December 15, 2016 Dec 15 2016
MediciNova Added to NASDAQ Biotechnology Index Dec 14 2016
MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166... Dec 09 2016
MEDICINOVA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 10 2016
MediciNova Announces European Medicines Agency Recommends Orphan Medicinal Product Designation for... Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)